DK1207875T3 - Farmaceutisk stabilt oxaliplatin-præparat til parenteral administration - Google Patents

Farmaceutisk stabilt oxaliplatin-præparat til parenteral administration

Info

Publication number
DK1207875T3
DK1207875T3 DK00952835T DK00952835T DK1207875T3 DK 1207875 T3 DK1207875 T3 DK 1207875T3 DK 00952835 T DK00952835 T DK 00952835T DK 00952835 T DK00952835 T DK 00952835T DK 1207875 T3 DK1207875 T3 DK 1207875T3
Authority
DK
Denmark
Prior art keywords
parenteral administration
preparation
pharmaceutically stable
solution
stable oxaliplatin
Prior art date
Application number
DK00952835T
Other languages
English (en)
Inventor
Houssam Ibrahim
Martine Bayssas
Henri Pourrat
Christine Deuschel
Original Assignee
Debiopharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Sa filed Critical Debiopharm Sa
Application granted granted Critical
Publication of DK1207875T3 publication Critical patent/DK1207875T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK00952835T 1999-08-30 2000-08-30 Farmaceutisk stabilt oxaliplatin-præparat til parenteral administration DK1207875T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15135799P 1999-08-30 1999-08-30
PCT/CH2000/000462 WO2001015691A1 (fr) 1999-08-30 2000-08-30 Preparation pharmaceutique stable d'oxaliplatine pour administration par voie parenterale

Publications (1)

Publication Number Publication Date
DK1207875T3 true DK1207875T3 (da) 2004-01-19

Family

ID=22538394

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00952835T DK1207875T3 (da) 1999-08-30 2000-08-30 Farmaceutisk stabilt oxaliplatin-præparat til parenteral administration

Country Status (19)

Country Link
EP (1) EP1207875B1 (da)
JP (1) JP4890711B2 (da)
KR (1) KR100688217B1 (da)
CN (1) CN1170533C (da)
AT (1) ATE249825T1 (da)
AU (1) AU768169B2 (da)
BR (1) BRPI0013613B8 (da)
CA (1) CA2382389C (da)
CZ (1) CZ298581B6 (da)
DE (1) DE60005376T2 (da)
DK (1) DK1207875T3 (da)
ES (1) ES2206288T3 (da)
HK (1) HK1048266B (da)
MX (1) MXPA02002266A (da)
PT (1) PT1207875E (da)
RU (1) RU2252022C2 (da)
UA (1) UA71985C2 (da)
WO (1) WO2001015691A1 (da)
ZA (1) ZA200200800B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1341555A2 (fr) 2000-12-12 2003-09-10 Debiopharm S.A. Preparation pharmaceutique d'oxaliplatine pour administration par voie parenterale et procede d'obtention de ladite preparation
TWI236486B (en) * 2001-10-10 2005-07-21 Mitsui Chemicals Inc Crosslinkable aromatic resin having protonic acid group, and ion conductive polymer membrane, binder and fuel cell using the resin
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
DE10314377A1 (de) * 2003-03-28 2004-10-07 Stada Arzneimittel Ag Gebrauchsfertige Oxaliplatin-Lösungen
EP2243480A1 (en) * 2003-08-28 2010-10-27 Mayne Pharma Pty Ltd Pharmaceutical formulations comprising oxaliplatin and an acid.
CZ300795B6 (cs) * 2003-09-02 2009-08-12 Pliva-Lachema A. S. Farmaceutická kompozice a zpusob její výroby
US7576126B2 (en) 2003-11-25 2009-08-18 Platco Technologies (Proprietary) Limited Platinum (II) complexes, preparation and use
AU2005278924A1 (en) 2004-09-01 2006-03-09 Platco Technologies (Proprietary) Limited Preparation of platinum(II) complexes
DE102004052877B4 (de) * 2004-11-02 2008-06-19 Ebewe Pharma Ges.M.B.H. Nfg.Kg Stabile wässrige Formulierungen eines Platin-Derivats
CN1311818C (zh) * 2004-11-22 2007-04-25 山东蓝金生物工程有限公司 一种抗实体肿瘤的药物组合物
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
WO2007029268A2 (en) 2005-09-05 2007-03-15 Dabur Pharma Limited Stable oxaliplatin formulation
BRPI0708004A2 (pt) 2006-01-30 2011-05-17 Platco Technologies Proprietary Ltd preparação de complexos de platina (ii)
CZ300664B6 (cs) * 2007-01-22 2009-07-15 Pliva-Lachema A. S. Sterilní kapalná farmaceutická kompozice a zpusob její výroby
CZ300665B6 (cs) * 2007-01-22 2009-07-15 Pliva-Lachema A. S. Sterilní kapalná farmaceutická kompozice a zpusob její výroby
KR200449655Y1 (ko) * 2009-11-20 2010-07-28 김명환 보조손잡이캡이 부설된 밀폐형 접이식 우산
KR101530942B1 (ko) * 2010-03-18 2015-06-23 이노파르마, 인코포레이티드 안정한 보르테조밉 포뮬레이션
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
CN102670526B (zh) * 2012-05-10 2013-12-04 南京臣功制药股份有限公司 奥沙利铂冻干粉针剂及其制备方法
JP5314790B1 (ja) * 2012-07-09 2013-10-16 東和薬品株式会社 オキサリプラチン含有医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5416394A (en) * 1992-11-24 1994-06-22 Debiopharm S.A. Cisplatinum/oxaliplatinum combination
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
ES2152412T3 (es) * 1994-08-08 2001-02-01 Debiopharm Sa Preparacion farmaceuticamente estable de oxaliplatino.
PT1014990E (pt) * 1997-03-07 2006-11-30 Sanofi Aventis Us Llc Associação antitumoral de 1, 4-dióxido de 3-amino-1,2,4-benzotriazina/paclitaxel/platina.
JP3774043B2 (ja) * 1997-09-12 2006-05-10 彰 辻 悪性腫瘍診断剤
GB9804013D0 (en) * 1998-02-25 1998-04-22 Sanofi Sa Formulations

Also Published As

Publication number Publication date
EP1207875B1 (fr) 2003-09-17
CZ298581B6 (cs) 2007-11-14
KR100688217B1 (ko) 2007-02-28
BR0013613A (pt) 2002-05-14
HK1048266A1 (en) 2003-03-28
AU768169B2 (en) 2003-12-04
JP2003508436A (ja) 2003-03-04
KR20020033782A (ko) 2002-05-07
WO2001015691A1 (fr) 2001-03-08
MXPA02002266A (es) 2003-08-20
ZA200200800B (en) 2003-06-25
BR0013613B1 (pt) 2013-05-28
CN1371278A (zh) 2002-09-25
PT1207875E (pt) 2004-02-27
JP4890711B2 (ja) 2012-03-07
CZ2002291A3 (cs) 2002-10-16
CN1170533C (zh) 2004-10-13
BRPI0013613B8 (pt) 2021-05-25
CA2382389A1 (fr) 2001-03-08
RU2252022C2 (ru) 2005-05-20
AU6553000A (en) 2001-03-26
EP1207875A1 (fr) 2002-05-29
ES2206288T3 (es) 2004-05-16
ATE249825T1 (de) 2003-10-15
HK1048266B (zh) 2005-04-01
DE60005376D1 (de) 2003-10-23
DE60005376T2 (de) 2004-07-01
CA2382389C (fr) 2010-06-29
UA71985C2 (uk) 2005-01-17

Similar Documents

Publication Publication Date Title
DK1207875T3 (da) Farmaceutisk stabilt oxaliplatin-præparat til parenteral administration
Catimel et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors
EP0261429B1 (en) Penetration enhancement systems and the preparation thereof
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
NO961136L (no) Farmasöytisk formuleringsgrunnlag for nano-suspensjoner
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
ES2154661T3 (es) Preparados liquidos que contienen cyclosporin y procedimiento para su obtencion.
IL140930A0 (en) Compounds and compositions for delivering active agents
DK1030670T3 (da) Anvendelse af vitamin D-derivater til forstærkning af virkningen af cytotoksiske midler
GR890100467A (el) Μεθοδος δια την παρασκευη ενδοφλεβιου φαρμακευτικης συνθεσεως.
HU9601846D0 (en) Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
WO2002015903A3 (de) Neue pharmazeutische zusammensetzung zur verabreichung von n-0923
BG104560A (en) Long active injectable formulations containing hydrogenated castor oil
MY111841A (en) Injectable liposomal pharmaceutical preparations
WO2001013909A3 (en) Compositions and methods for treating opiate intolerance
MY132911A (en) Clear, injectable solution of an anesthetic compound
Gabrielsson et al. Constant-rate infusion of nicotine and cotinine. I. A physiological pharmacokinetic analysis of the cotinine disposition, and effects on clearance and distribution in the rat
Kestell et al. Disposition of amsacrine and its analogue 9-({; 2-methoxy-4-[(methylsulfonyl)-amino] phenyl} amino)-N, 5-dimethyl-4-acridinecarboxamide (CI-921) in plasma, liver, and lewis lung tumors in mice
KR20010102240A (ko) 니코틴 의존증 치료를 위한 데옥시페가닌을 포함하는 약학조성물
AU1704801A (en) Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating cancer
TOKUNAGA et al. Liposomal Sustained-Release Delivery Systems for Intravenous Injection. V. Biological Disposition of Liposome-Entrapped Lipophilic Prodrug of 1-β-Darabinofuranosylcytosine
Hansch et al. Acknowledgment. This work was supported by US
WO2004050019A9 (en) Method and compositions for treating anxiety
NZ503559A (en) Compositions and methods for the control of smoking containing a xanthine oxidase inhibitor